Czech National Bank Acquires 27,039 Shares of Merck & Co., Inc. $MRK

Czech National Bank raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 703,007 shares of the company's stock after acquiring an additional 27,039 shares during the quarter. Czech National Bank's holdings in Merck & Co., Inc. were worth $90,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of MRK. Norges Bank bought a new position in Merck & Co., Inc. in the 4th quarter worth $3,997,933,000. Wellington Management Group LLP lifted its position in Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. bought a new stake in Merck & Co., Inc. during the fourth quarter valued at about $1,012,530,000. Jennison Associates LLC bought a new stake in Merck & Co., Inc. during the fourth quarter valued at about $585,192,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Merck & Co., Inc. by 37.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company's stock valued at $1,973,983,000 after purchasing an additional 5,152,069 shares during the period. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

MRK stock opened at $128.27 on Friday. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05. The company's fifty day moving average price is $123.78 and its 200-day moving average price is $119.04. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market capitalization of $316.81 billion, a PE ratio of 102.62, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. Merck & Co., Inc.'s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.72 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

Wall Street Analyst Weigh In

MRK has been the topic of several recent research reports. Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Royal Bank Of Canada reiterated an "outperform" rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 8th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Finally, Morgan Stanley upped their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $134.56.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source